While wild poliovirus (WPV) is widely known, circulating vaccine-derived poliovirus (cVDPV) is another form of polio that can spread within communities due to low immunization rates. cVDPVs, though rare, have been on the rise in recent years. The most common strain, cVDPV type 2 (cVDPV2), saw a global increase to 959 cases in 2020. With the African Region declared WPV-free in August 2020, cVDPVs are now the predominant form of poliovirus affecting the region.
The Impact of Oral Polio Vaccine
The oral polio vaccine (OPV) has played a crucial role in nearly eradicating wild poliovirus. The live attenuated vaccine virus provides strong gut immunity, essential for combating poliovirus replication. However, in communities with low immunization rates, prolonged virus transmission among unvaccinated individuals can lead to mutations and the development of cVDPVs.
Preventing cVDPVs hinges on maintaining high immunization rates. The polio vaccine, whether for WPV or cVDPV, offers vital protection. Outbreaks can be effectively contained with targeted immunization campaigns and the deployment of improved vaccines like nOPV2.
Persistent Vaccine-Derived Polioviruses
Prolonged replication of vaccine-derived polioviruses has been observed in individuals with rare immune deficiencies. These individuals are unable to clear the virus, leading to prolonged excretion. While rare, these cases underscore the importance of maintaining high vaccination coverage.
In order to prevent the occurrence of persistent vaccine-derived polioviruses, it is essential for communities to maintain high levels of vaccination coverage. This not only helps protect individuals with immune deficiencies but also contributes to the overall eradication of polioviruses.
Health authorities recommend regular vaccination schedules for children and adults to ensure herd immunity and prevent the reemergence of polioviruses. Additionally, continued surveillance and monitoring of vaccine-derived polioviruses are crucial in identifying and managing cases of prolonged replication.
Despite the tremendous progress made in eradicating polio through vaccination efforts, challenges still remain. One of the main obstacles is the emergence of vaccine-derived polioviruses (VDPVs), including aVDPVs, which can circulate in populations with low immunity levels.
In addition to vaccination campaigns, surveillance systems play a crucial role in detecting and responding to any cases of VDPVs. Monitoring the genetic evolution of the virus helps health authorities track its spread and implement targeted interventions to prevent outbreaks.
Educating communities about the importance of vaccination and maintaining high immunization coverage is essential to ensure the continued success of global polio eradication efforts. By staying informed, vigilant, and proactive, we can overcome the remaining challenges and achieve a polio-free world for future generations.
The Role of Polio Vaccines
Vaccines, like the oral polio vaccine (OPV) and the inactivated polio vaccine (IPV), are highly effective in preventing polio. OPV offers broader community protection, while IPV is more targeted at individual immunity. Improved vaccines are continuously developed to address emerging challenges posed by vaccine-derived polioviruses.
The progress in eradicating polio hinges on sustained vaccination efforts and high vaccine coverage. By vaccinating every child, communities can collectively prevent the spread of both wild and vaccine-derived polio.
Great strides have been made in the fight against polio, emphasizing the critical need for widespread vaccination to achieve global eradication.
Understanding the Impact of cVDPVs
Circulating vaccine-derived polioviruses (cVDPVs) continue to pose a threat in communities with low immunity. Recent data shows a rise in cVDPV outbreaks globally, underscoring the need for prompt outbreak responses and improved immunization efforts.
Altmetric:
Challenges in Poliovirus Eradication
Between January 2023 and June 2024, a total of 74 cVDPV outbreaks were identified in 39 countries, predominantly in Africa. Out of these outbreaks, 47 were new and reported in 30 of the 39 countries. The majority of outbreaks were cVDPV2, with only three countries experiencing cVDPV1 outbreaks. Interestingly, two countries had both cVDPV1 and cVDPV2 outbreaks. Among the 38 countries with cVDPV2 transmission, there were 70 separate outbreaks reported. In 15 countries, cVDPV transmission persisted into 2024 for over a year. Nigeria and Somalia faced challenges with cVDPV2 transmission spreading to neighboring countries due to delays in response campaigns.
The long-lasting protection provided by the live oral poliovirus vaccine against paralysis and reduced virus shedding in vaccinated individuals is crucial in preventing cVDPV outbreaks. Following the eradication of wild poliovirus type 2 in 2015, countries switched to bivalent OPV to minimize the risk of cVDPV2 outbreaks. The recommended use of the novel oral poliovirus vaccine type 2 in response to cVDPV2 outbreaks has been hindered by limited supplies, leading to ongoing outbreaks despite efforts to change vaccines.
Data on cVDPV outbreaks and control measures were gathered from the World Health Organization Polio Information System and Global Polio Laboratory Network. Detection of a cVDPV outbreak requires multiple confirmations of genetically linked VDPV through various surveillance methods. Successful interruption of outbreaks is achieved when no new cases are detected for over 13 months.
A total of 74 cVDPV outbreaks were reported, with 672 AFP cases in 27 countries during the reporting period. Declines in cVDPV AFP cases, particularly cVDPV1, were noted. Some countries reported simultaneous circulation of cVDPV1 and cVDPV2, with no new cVDPV3 cases detected.
Efforts to control cVDPV outbreaks have not significantly reduced the number of affected countries, with new outbreaks continuing to arise. Challenges in vaccine supply, logistics, and access have hindered outbreak responses, emphasizing the need for enhanced surveillance and rapid intervention.
In conclusion, the push to end all cVDPV transmission by 2026 underscores the urgency in responding promptly to new outbreaks and collaborating effectively with humanitarian agencies to vaccinate children in difficult-to-reach areas. Addressing gaps in poliovirus surveillance and strengthening outbreak response capabilities are crucial steps towards achieving this goal.